Selected research
Industry Research
Pneumococcal Conjugate Vaccine (PCV) Industry Research Report 2026
Market perspective
The global Pneumococcal Conjugate Vaccine (PCV) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Pneumococcal Conjugate Vaccine (PCV) market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Pneumococcal Conjugate Vaccine (PCV) market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Pneumococcal Conjugate Vaccine (PCV) market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Pneumococcal Conjugate Vaccine (PCV) include Sanofi, Merck, Pfizer, GSK, Zhifei Biologic, Walvax Biotechnology, Serum Institute of India and Royal (Wuxi) Bio-Pharmaceutical, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Pneumococcal Conjugate Vaccine (PCV) market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Pneumococcal Conjugate Vaccine (PCV).
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pneumococcal Conjugate Vaccine (PCV) Market by Company
Sanofi
Merck
Pfizer
GSK
Zhifei Biologic
Walvax Biotechnology
Serum Institute of India
Royal (Wuxi) Bio-Pharmaceutical
Pneumococcal Conjugate Vaccine (PCV) Segment by Type
10-valent Vaccine
13-valent Vaccine
23-valent Vaccine
7-valent Vaccine
Pneumococcal Conjugate Vaccine (PCV) Segment by Application
Child
Adult
Pneumococcal Conjugate Vaccine (PCV) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal Conjugate Vaccine (PCV) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal Conjugate Vaccine (PCV) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal Conjugate Vaccine (PCV).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Pneumococcal Conjugate Vaccine (PCV) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 10-valent Vaccine
- 13-valent Vaccine
- 23-valent Vaccine
- 7-valent Vaccine
Applications
- Child
- Adult
Companies covered
- Sanofi
- Merck
- Pfizer
- GSK
- Zhifei Biologic
- Walvax Biotechnology
- Serum Institute of India
- Royal (Wuxi) Bio-Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Pneumococcal Conjugate Vaccine (PCV) by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 10-valent Vaccine
- 2.2.3 13-valent Vaccine
- 2.2.4 23-valent Vaccine
- 2.2.5 7-valent Vaccine
- 2.3 Pneumococcal Conjugate Vaccine (PCV) by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Child
- 2.3.3 Adult
- 2.4 Assumptions and Limitations
3 Pneumococcal Conjugate Vaccine (PCV) Breakdown Data by Type
- 3.1 Global Pneumococcal Conjugate Vaccine (PCV) Historic Market Size by Type (2021-2026)
- 3.2 Global Pneumococcal Conjugate Vaccine (PCV) Forecasted Market Size by Type (2027-2032)
4 Pneumococcal Conjugate Vaccine (PCV) Breakdown Data by Application
- 4.1 Global Pneumococcal Conjugate Vaccine (PCV) Historic Market Size by Application (2021-2026)
- 4.2 Global Pneumococcal Conjugate Vaccine (PCV) Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Pneumococcal Conjugate Vaccine (PCV) Market Perspective (2021-2032)
- 5.2 Global Pneumococcal Conjugate Vaccine (PCV) Growth Trends by Region
- 5.2.1 Global Pneumococcal Conjugate Vaccine (PCV) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Pneumococcal Conjugate Vaccine (PCV) Historic Market Size by Region (2021-2026)
- 5.2.3 Pneumococcal Conjugate Vaccine (PCV) Forecasted Market Size by Region (2027-2032)
- 5.3 Pneumococcal Conjugate Vaccine (PCV) Market Dynamics
- 5.3.1 Pneumococcal Conjugate Vaccine (PCV) Industry Trends
- 5.3.2 Pneumococcal Conjugate Vaccine (PCV) Market Drivers
- 5.3.3 Pneumococcal Conjugate Vaccine (PCV) Market Challenges
- 5.3.4 Pneumococcal Conjugate Vaccine (PCV) Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Pneumococcal Conjugate Vaccine (PCV) Players by Revenue
- 6.1.1 Global Top Pneumococcal Conjugate Vaccine (PCV) Players by Revenue (2021-2026)
- 6.1.2 Global Pneumococcal Conjugate Vaccine (PCV) Revenue Market Share by Players (2021-2026)
- 6.2 Global Pneumococcal Conjugate Vaccine (PCV) Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Pneumococcal Conjugate Vaccine (PCV) Head Office and Area Served
- 6.4 Global Pneumococcal Conjugate Vaccine (PCV) Players, Product Type & Application
- 6.5 Global Pneumococcal Conjugate Vaccine (PCV) Manufacturers Established Date
- 6.6 Global Pneumococcal Conjugate Vaccine (PCV) Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032)
- 7.2 North America Pneumococcal Conjugate Vaccine (PCV) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026)
- 7.4 North America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032)
- 8.2 Europe Pneumococcal Conjugate Vaccine (PCV) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026)
- 8.4 Europe Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032)
- 9.2 Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032)
- 10.2 South America Pneumococcal Conjugate Vaccine (PCV) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026)
- 10.4 South America Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size (2021-2032)
- 11.2 Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Pneumococcal Conjugate Vaccine (PCV) Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Sanofi
- 12.1.1 Sanofi Company Information
- 12.1.2 Sanofi Business Overview
- 12.1.3 Sanofi Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026)
- 12.1.4 Sanofi Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
- 12.1.5 Sanofi Recent Developments
- 12.2 Merck
- 12.2.1 Merck Company Information
- 12.2.2 Merck Business Overview
- 12.2.3 Merck Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026)
- 12.2.4 Merck Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
- 12.2.5 Merck Recent Developments
- 12.3 Pfizer
- 12.3.1 Pfizer Company Information
- 12.3.2 Pfizer Business Overview
- 12.3.3 Pfizer Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026)
- 12.3.4 Pfizer Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
- 12.3.5 Pfizer Recent Developments
- 12.4 GSK
- 12.4.1 GSK Company Information
- 12.4.2 GSK Business Overview
- 12.4.3 GSK Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026)
- 12.4.4 GSK Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
- 12.4.5 GSK Recent Developments
- 12.5 Zhifei Biologic
- 12.5.1 Zhifei Biologic Company Information
- 12.5.2 Zhifei Biologic Business Overview
- 12.5.3 Zhifei Biologic Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026)
- 12.5.4 Zhifei Biologic Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
- 12.5.5 Zhifei Biologic Recent Developments
- 12.6 Walvax Biotechnology
- 12.6.1 Walvax Biotechnology Company Information
- 12.6.2 Walvax Biotechnology Business Overview
- 12.6.3 Walvax Biotechnology Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026)
- 12.6.4 Walvax Biotechnology Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
- 12.6.5 Walvax Biotechnology Recent Developments
- 12.7 Serum Institute of India
- 12.7.1 Serum Institute of India Company Information
- 12.7.2 Serum Institute of India Business Overview
- 12.7.3 Serum Institute of India Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026)
- 12.7.4 Serum Institute of India Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
- 12.7.5 Serum Institute of India Recent Developments
- 12.8 Royal (Wuxi) Bio-Pharmaceutical
- 12.8.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
- 12.8.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
- 12.8.3 Royal (Wuxi) Bio-Pharmaceutical Revenue in Pneumococcal Conjugate Vaccine (PCV) Business (2021-2026)
- 12.8.4 Royal (Wuxi) Bio-Pharmaceutical Pneumococcal Conjugate Vaccine (PCV) Product Portfolio
- 12.8.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst